Print

siRNA positive and negative controls

Research Diagnostic Therapeutic
In order to monitor your siRNA experiment conditions, Eurogentec provides siRNA control duplexes and kits.


Name Synthesis scale Purification Reference EUR
Lamin B1 (human) 5 nmol PAGE OR-0030-lamin05 57.50
Vimentin (human) 5 nmol PAGE OR-0030-vimentin05 57.50
NuMA (human) 5 nmol PAGE OR-0030-numa05 57.50
Beta-actin (human) 5 nmol PAGE OR-0030-actin05 57.50
Eg-5 (human) 5 nmol PAGE OR-0030-eg505 57.50
Cdk-1 (human) 5 nmol PAGE OR-0030-cdk105 57.50
pGL2 luciferase (firefly) 5 nmol PAGE OR-0030-GL205 57.50
pGL3 luciferase (firefly) 5 nmol PAGE OR-0030-GL305 57.50
GFP (jellyfish) 5 nmol PAGE OR-0030-GFP05 57.50
Negative control 5 nmol PAGE OR-0030-neg05 57.50
Price per single individual siRNA control duplex

Quality Control

   MALDI-TOF Mass Spectrometry

Delivery times

   5 Working days

Packaging

   Lyophylised

Shipping conditions

   Room temperature

Storage conditions

   -20 °C to -70 °C
Store siRNA oligos as a dry pellet at -20°C (or preferably -70°C) in a non-frost free freezer until ready to use. Once resuspended in RNase-free buffer, store at -70°C and avoid contact with RNases. siRNA oligos should be resuspended to a convenient stock concentration (20 to 50 µM) and stored in small aliquots to avoid multiple freeze thaw cycles. When stored under these conditions and using good RNase-free technique, they typically remain stable for 6 months or more. The solution can be freeze-thawed up to 5 times. For long-term storage, siRNA oligos should be dried.

As for any valid experiment, negative and positive controls are necessary

Two kinds of negative controls may be used. First, a parallel experiment with a scrambled sequence of the siRNA of interest can be made. It is also possible to perform this control with a siRNA containing one to three mismatches in the sequence of interest. This control allows to check the specificity of the siRNA of interest. Second, it is possible to use a perfectly unique sequence which should not match to any sequence in the genome of interest, this to show the correlation between the siRNA of interest and the silencing effect. It is advised to use this negative control in every experiment.

Positive controls are also necessary to prove the validity of the principle and to ensure that the quality of the experiment was suitable to perform an RNAi assay. Moreover it allows to normalize the result obtained. In order to perform this control, some validated and published sequences are mainly used. 


Eurogentec is proposing ready-to-use control sequences

siRNA directed against a range of endogenous and reporter genes are available in 5, 10 and 20 nmol final quantities. Each control contains 1 siRNA duplex. All siRNA control duplexes are PAGE purified and 100 % MALDI-TOF Mass Spectrometry controlled.The sequences proposed are validated and published (see the references below).

A proprietary negative control :
  • Validated proprietary sequence
  • No homology with any known eukaryotic gene
  • Ready-to-use : already annealed and shipped in solution

Legal notices

   For Research Use only

Product citations


POTENTE M. et al., "11,12-Epoxyeicosatrienoic Acid-induced Inhibition of FOXO Factors Promotes Endothelial Proliferation by Down-Regulating p27Kip1", Journal of Biological Chemistry, vol. 278, n° 32, p. 29619-29625, May 2003


TUROWSKI P. et al., "Functional cdc25C Dual-Specificity Phosphatase Is Required for S-Phase Entry in Human Cells", Molecular Biology of the Cell, vol. 14, Issue 7, p. 2984-2998, July 2003


AVEROUST J. et al., "Induction of CHOP Expression by Amino Acid Limitation Requires Both ATF4 Expression ATF2 Phosphorylation", Journal of Biological Chemistry, vol. 279, n° 7, p. 5288-5297, February 2004


LAZRAK M. et al., "The bHLH TAL-1/SCL regulates endothelial cell migration and morphogenesis", Journal of Cell Science, 117, 1161-1171, February 2004


DUTTON A. et al., "Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death", PNAS, vol. 101, n° 17, p. 6611-6616, April 2004


VOURET-CRAVIARI V. et al., "ILK is required for the assembly of matrix-forming adhesions and capillary morphogenesis in endothelial cells", Journal of Cell Science, 117, p. 4559-4569, May 2004


YU L.-G. et al., "Protein Phosphatase 2A, a Negative Regulator of the ERK Signaling Pathway, Is Activated by Tyrosine Phosphorylation of Putative HLA Class II-associated Protein I (PHAPI)/pp32 in Response to the Antiproliferative Lectin, Jacalin", Journal of Biological Chemistry, vol. 279, n° 40, p. 41377-41383, October 2004


STEWART S. et al., "Epstein–Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-B transcription factor pathway", PNAS, vol. 101, n° 44, 15730-15735, November 2004


LAIGLE A. et al., "The reduction of P-Glycoprotein Expression by small interfering RNAs is improved in exponentially growing cells", Oligonucleotides, 14:191-198, 2004


WÜNSCHE W. et al., "The activity of siRNA in Mammalian Cells is related to the kinetics of siRNA-target recognition in vitro: Mechanistic Implications", Journal of Molecular Biology, vol. 345, 203-209, 2005


LOUIS K. et al., "Tumor Cell-mediated Induction of the Stromal Factor Stromelysin-3 Requires Heterotypic Cell Contact-dependent Activation of Specific Protein Kinase C Isoforms", Journal of Biological Chemistry, vol. 280, n° 2, p. 1272-1283, January 2005





  • Online
    You can place your order online. Login to access our web ordering interface.
  • By fax : +32 4 264 07 88
  • By mail
    Eurogentec S.A.
    LIEGE Science Park
    Rue du Bois Saint Jean 5
    4102 Seraing
    BELGIUM

If you still have questions with ordering please contact our Customer Support : +32 4 372 76 65.

To receive relevant information on our products, you should first select your country :
Country selection page